Legend Biotech reported strong third-quarter 2026 financial results, with revenue of $359.5 million and adjusted EPS of $0.14. The significant growth in CARVYKTI sales, up 36% year-over-year to $710 million, indicates robust demand for its key cell therapy and suggests positive momentum for the company's future performance.
Legend Biotech announced its Q3 2026 financial results, reporting $359.5 million in revenue and $0.14 adjusted EPS. The most significant highlight was the 36% year-over-year growth in net trade sales for its CARVYKTI cell therapy, reaching $710 million. This strong performance indicates successful commercialization and increasing market penetration for a critical product, which is a major positive for LEGN. As Johnson & Johnson (JNJ) is a partner in CARVYKTI, they also benefit from its success. Short-term, this news could lead to a positive stock reaction for LEGN due to exceeding expectations and demonstrating strong product demand. Long-term, continued CARVYKTI growth and pipeline advancements, including data from CARTITUDE-2, position Legend Biotech for sustained revenue growth and market leadership in cell therapy, though execution risks in pipeline development always remain.